249 related articles for article (PubMed ID: 34250760)
41. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
42. Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis.
Swellam M; Bakr NM; El Magdoub HM; Hamza MS; Ezz El Arab LR
J Mol Neurosci; 2021 Apr; 71(4):836-844. PubMed ID: 32989634
[TBL] [Abstract][Full Text] [Related]
43. Does the expression of glial fibrillary acid protein (GFAP) stain in glioblastoma tissue have a prognostic impact on survival?
Ahmadipour Y; Gembruch O; Pierscianek D; Sure U; Jabbarli R
Neurochirurgie; 2020 Jun; 66(3):150-154. PubMed ID: 32278699
[TBL] [Abstract][Full Text] [Related]
44. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
45. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
[TBL] [Abstract][Full Text] [Related]
46. Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics.
Miyauchi E; Furuta T; Ohtsuki S; Tachikawa M; Uchida Y; Sabit H; Obuchi W; Baba T; Watanabe M; Terasaki T; Nakada M
PLoS One; 2018; 13(3):e0193799. PubMed ID: 29513714
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
[TBL] [Abstract][Full Text] [Related]
48. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma.
Marfia G; Navone SE; Fanizzi C; Tabano S; Pesenti C; Abdel Hadi L; Franzini A; Caroli M; Miozzo M; Riboni L; Rampini P; Campanella R
Cancer Med; 2016 Aug; 5(8):1783-90. PubMed ID: 27236861
[TBL] [Abstract][Full Text] [Related]
50. Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients.
Yan JL; van der Hoorn A; Larkin TJ; Boonzaier NR; Matys T; Price SJ
J Neurosurg; 2017 Jan; 126(1):234-241. PubMed ID: 27058207
[TBL] [Abstract][Full Text] [Related]
51. Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients.
Wang X; Zhang K; Chen X; Zhao C; Sun Z
Med Oncol; 2015 Jan; 32(1):363. PubMed ID: 25429835
[TBL] [Abstract][Full Text] [Related]
52. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.
Preusser M; Charles Janzer R; Felsberg J; Reifenberger G; Hamou MF; Diserens AC; Stupp R; Gorlia T; Marosi C; Heinzl H; Hainfellner JA; Hegi M
Brain Pathol; 2008 Oct; 18(4):520-32. PubMed ID: 18400046
[TBL] [Abstract][Full Text] [Related]
53. [Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
Lobanova NV; Shishkina LV; Ryzhova MV; Kobyakov GL; Sycheva RV; Burov SA; Lukyanov AV; Omarova ZR
Arkh Patol; 2016; 78(4):10-19. PubMed ID: 27600777
[TBL] [Abstract][Full Text] [Related]
54. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
55. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma.
Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A
World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096
[TBL] [Abstract][Full Text] [Related]
56. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
[TBL] [Abstract][Full Text] [Related]
57. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
58. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
59. Analysis of Glioblastoma Patients' Plasma Revealed the Presence of MicroRNAs with a Prognostic Impact on Survival and Those of Viral Origin.
Herman A; Gruden K; Blejec A; Podpečan V; Motaln H; Rožman P; Hren M; Zupančič K; Veber M; Verbovšek U; Lah Turnšek T; Porčnik A; Koršič M; Knežević M; Jeras M
PLoS One; 2015; 10(5):e0125791. PubMed ID: 25950799
[TBL] [Abstract][Full Text] [Related]
60. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]